Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| 1 |
Moderna
MRNA
|
$903M |
| 2 |
Charles Schwab
SCHW
|
$631M |
| 3 |
Affirm
AFRM
|
$556M |
| 4 |
FTCH
Farfetch Limited Class A Ordinary Shares
FTCH
|
$514M |
| 5 |
Coupang
CPNG
|
$458M |
Top Sells
| 1 |
Tesla
TSLA
|
$3.23B |
| 2 |
Full Truck Alliance
YMM
|
$995M |
| 3 |
ResMed
RMD
|
$718M |
| 4 |
NVIDIA
NVDA
|
$691M |
| 5 |
Amazon
AMZN
|
$509M |
Sector Composition
| 1 | Consumer Discretionary | 26.58% |
| 2 | Healthcare | 23.23% |
| 3 | Technology | 21.05% |
| 4 | Communication Services | 12.81% |
| 5 | Financials | 5.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
326
Goodyear
GT
$2.43B
| $30K | ﹤0.01% |
1,400
| – | – |
|
|
BRSL
327
Brightstar Lottery PLC
BRSL
$3.18B
| $30K | ﹤0.01% |
1,024
-76
| -7% | -$2.23K |
|
328
Intuit
INTU
$188B
| $30K | ﹤0.01% |
+47
| New | +$30K |
|
329
Kulicke & Soffa
KLIC
$1.99B
| $30K | ﹤0.01% |
491
| – | – |
|
330
MaxLinear
MXL
$1.36B
| $30K | ﹤0.01% |
+400
| New | +$30K |
|
331
Pfizer
PFE
$141B
| $30K | ﹤0.01% |
500
| – | – |
|
332
Adeia
ADEA
$1.69B
| $29K | ﹤0.01% |
5,855
-923
| -14% | -$4.57K |
|
333
Graco
GGG
$14.2B
| $29K | ﹤0.01% |
363
| – | – |
|
334
Regeneron Pharmaceuticals
REGN
$60.8B
| $29K | ﹤0.01% |
46
-9
| -16% | -$5.67K |
|
335
Cohen & Steers
CNS
$3.7B
| $28K | ﹤0.01% |
301
-24
| -7% | -$2.23K |
|
336
Exponent
EXPO
$3.61B
| $28K | ﹤0.01% |
242
| – | – |
|
337
Knowles
KN
$1.85B
| $28K | ﹤0.01% |
1,200
| – | – |
|
|
INFN
338
DELISTED
Infinera Corporation Common Stock
INFN
| $28K | ﹤0.01% |
2,941
| – | – |
|
339
Bristol-Myers Squibb
BMY
$96B
| $27K | ﹤0.01% |
427
-47
| -10% | -$2.97K |
|
340
Cohu
COHU
$950M
| $27K | ﹤0.01% |
700
| – | – |
|
341
Amdocs
DOX
$9.46B
| $27K | ﹤0.01% |
365
| – | – |
|
342
SEI Investments
SEIC
$10.8B
| $27K | ﹤0.01% |
438
+38
| +10% | +$2.34K |
|
343
AppFolio
APPF
$10.2B
| $26K | ﹤0.01% |
212
-29
| -12% | -$3.56K |
|
344
BlackBerry
BB
$2.31B
| $26K | ﹤0.01% |
2,731
| – | – |
|
345
Box
BOX
$4.75B
| $26K | ﹤0.01% |
979
| – | – |
|
346
Donaldson
DCI
$9.44B
| $26K | ﹤0.01% |
+436
| New | +$26K |
|
347
Humana
HUM
$37B
| $26K | ﹤0.01% |
56
| – | – |
|
348
Visteon
VC
$3.41B
| $26K | ﹤0.01% |
230
+30
| +15% | +$3.39K |
|
349
Quest Diagnostics
DGX
$20.5B
| $25K | ﹤0.01% |
145
| – | – |
|
|
VNE
350
DELISTED
Veoneer, Inc.
VNE
| $25K | ﹤0.01% |
700
| – | – |
|